To determine the impact of Brg1 and/or Brm loss on cancer development, we generated four molecular phenotypes, as follows: wild type (control: Brg1+/+Brm+/+), Brm-null (Brg1+/+Brm−/−), Brg1- knockout (Brg1-KO, Brg1−/−Brm+/+) and Brg1/Brm-deficient (double knockout mice, DKO: Brg1−/−Brm−/−) (Figure 1A). Here, SMARCA2 is linked to cancer.